HTG Molecular Diagnostics, Inc. (HTGM) Research

Based in Tucson, Arizona, HTG Molecular Diagnostics, Inc. is a life sciences company dedicated to advancing precision medicine. They provide a comprehensive suite of products, including specialized instruments, assay kit consumables, and software solutions, all designed to automate sample processing and accurately profile various molecular targets. Their extensive portfolio features numerous molecular profiling panels, such as the HTG Transcriptome Panel, HTG EdgeSeq precision immuno-oncology panel, HTG EdgeSeq miRNA whole-transcriptome assay, HTG EdgeSeq DLBCL cell of origin assay (available in both EU and non-EU versions), HTG EdgeSeq Oncology Biomarker Panel, HTG EdgeSeq ALKPlus assay EU, HTG EdgeSeq Pan B-Cell Lymphoma Panel, HTG immune response panel, and HTG mouse mRNA tumor response panel. The company directly distributes its instruments and consumables across the United States and Europe, while utilizing distributors for other international markets and specific European regions. Their diverse clientele includes biopharmaceutical companies, academic research centers, and molecular testing laboratories. Additionally, HTG Molecular Diagnostics, Inc. maintains a governing agreement with QIAGEN Manchester Limited. The company was founded in 1997 as HTG, Inc., and officially changed its name to HTG Molecular Diagnostics, Inc. in March 2011.

Open HTG Molecular Diagnostics, Inc. (HTGM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.